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Myocardial pathology induced by aldosterone is
dependent on non-canonical activities of G
protein-coupled receptor kinases
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Hyper-aldosteronism is associated with myocardial dysfunction including induction of cardiac
ﬁbrosis and maladaptive hypertrophy. Mechanisms of these cardiotoxicities are not
fully understood. Here we show that mineralocorticoid receptor (MR) activation by aldos-
terone leads to pathological myocardial signalling mediated by mitochondrial G
protein-coupled receptor kinase 2 (GRK2) pro-death activity and GRK5 pro-hypertrophic
action. Moreover, these MR-dependent GRK2 and GRK5 non-canonical activities appear to
involve cross-talk with the angiotensin II type-1 receptor (AT1R). Most importantly, we show
that ventricular dysfunction caused by chronic hyper-aldosteronism in vivo is completely
prevented in cardiac Grk2 knockout mice (KO) and to a lesser extent in Grk5 KO mice.
However, aldosterone-induced cardiac hypertrophy is totally prevented in Grk5 KO mice.
We also show human data consistent with MR activation status in heart failure inﬂuencing
GRK2 levels. Therefore, our study uncovers GRKs as targets for ameliorating pathological
cardiac effects associated with high-aldosterone levels.
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T
he classic neurohormonal model of heart failure (HF) is
rooted in the enhancement of molecules, such as
sympathetic catecholamine neurotransmitters and over-
activation of the renin–angiotensin–aldosterone system (RAAS).
Aldosterone, a hormone secreted by the adrenal cortex, is directly
involved in the regulation of blood pressure1. Aldosterone has
also been implicated in the pathogenesis of HF as patients have
markedly elevated plasma aldosterone concentrations2,3 and
increased aldosterone after myocardial infarction (MI) has been
implicated in HF progression4. Moreover, cardiac expression of
aldosterone’s mineralocorticoid receptor (MR) has been shown to
be elevated in HF patients5. In this regard, recent evidence
indicates that chronic exposure to high-aldosterone levels and
persistent activation of MRs can induce myocardial tissue
damage via mechanisms that are independent of blood pressure
elevation6. In fact, chronic infusion of aldosterone can lead to
increased cardiac ﬁbrosis7 and pathological hypertrophy5,7–9.
Accordingly, MR antagonists such as spironolactone and
eplerenone have emerged as key drugs in the armamentarium
against HF to combat cardiac dysfunction associated with chronic
hyper-aldosteronism10–12.
The underlying mechanisms of these deleterious effects are not
completely understood and thus, there is an urgency to uncover
molecular mechanisms involved in aldosterone-mediated cardiac
dysfunction to identify new molecular targets and improve
HF therapy. Recently, it has been shown that, through a
‘non-genomic’ mechanism, aldosterone can activate NADPH
oxidases (NOX2 and 4), thus increasing reactive oxygen species
(ROS) and eliciting an apoptotic and ﬁbrotic response13,14.
Intriguingly, some of the effects of aldosterone in the heart can be
attributed to a linkage with G protein-coupled receptor (GPCR)
signalling. In particular, it appears that aldosterone can activate
cross-talk between the MR15–18 and the angiotensin II (AngII)
type-1 receptor (AT1R), a GPCR critically involved in both
hypertension and HF progression19.
Since the AT1R is implicated in aldosterone-mediated cardiac
dysfunction, we posited that also GPCR kinases (GRKs), as
regulator of this receptor, may be involved in this deleterious
mechanism. In particular, we looked at GRK2 and GRK5, the
major GRKs found in the heart, since both have been linked to
HF development and progression20,21, and the levels of these
kinases are elevated in human failing myocardium22–24. Of note,
GRK2 but not GRK5, has been shown to desensitize AngII
responses in the heart25–27; however, recent evidence show that
these kinases can trigger pathological myocardial signalling
independent of direct GPCR regulation27–31. These non-
canonical GRK activities include the unique mitochondrial
localization of GRK2 promoting cell death29,30, and the
translocation of GRK5 within the nucleus of myocytes
promoting pathological hypertrophic gene transcription27,31.
The latter indeed occurs in the heart downstream of AT1R
activation27.
In this study, we have found that these non-GPCR activities
of GRK2 and GRK5 are directly involved in the pathological
MR-AT1R signalling axis in the heart. By using in vitro systems
and in vivo mouse models, we have uncovered a previously
unknown dependence of GRK2 and GRK5 within cardiomyocytes
in aldosterone-mediated cardiac dysfunction.
Results
Aldosterone activates myocyte AT1R signalling via c-Src/b-arrestin.
Aldosterone treatment of cardiomyocytes is associated with a
‘rapid’ ERK 1/2 activation response that has been suggested to
depend on the cross-talk between the MR and the AT1R18.
Indeed, in ventricular myocytes isolated from neonatal rats
(NRVMs), we found ERK activation by aldosterone peaking
after 15min (Fig. 1a). Importantly, pre-treatment of cells with
spironolactone, a MR antagonist, or losartan, an AT1R antagonist,
both could inhibit aldosterone-mediated ERK activation (Fig. 1a),
indicating MR-AT1R cross-talk. ERK activation via GPCRs, and
in particular the AT1R, can occur via both G protein-dependent
and G protein-independent pathways32. The latter occurs via the
combined action of, GRKs and b-ARRESTINs33. We therefore
performed experiments to establish whether aldosterone causes
AT1R-mediated b-arrestin recruitment and interestingly, found
to be the case (Fig. 1b). Membrane b-ARRESTIN localization
stimulated by aldosterone was attenuated with losartan pre-
treatment, suggesting aldosterone-mediated activation of the
AT1R endocytic machinery (Fig. 1b). Next, since C-SRC is
involved in aldosterone-mediated ERK activation34 and is crucial
for the b-ARRESTIN-mediated process of internalization and
signalling transduction of the AT1R, even in the absence of
agonist35, we assessed whether c-Src might play a role in this
mechanism. To test this, we used the Src family kinase inhibitor,
PP2 and we found that PP2-pre-treatment of cells could inhibit
aldosterone-mediated ERK activation in myocytes (Fig. 1c).
Further, using an adenovirus (Ad) carrying a HA-tagged AT1R
(Ad-HA-AT1R) cDNA we performed a co-immunoprecipitation
(Co-IP) assay to evaluate whether c-Src inhibition can affect the
b-ARRESTIN recruitment to the AT1R. In line with previous
results35, b-ARRESTIN recruitment was not affected in the
presence of PP2 (Fig. 1d). Moreover, using an Ad-HA-AT1R and
an Ad encoding for the MR to infect NRVMs, we found that
aldosterone can induce the internalization of the AT1R similar
to the receptor internalization induced by AngII (Fig. 1e).
Interestingly, spironolactone, losartan as well as PP2 blocked
aldosterone-mediated AT1R internalization (Fig. 1e). Thus, both
AT1R internalization and ERK activation induced by aldosterone
is C-SRC-dependent and appears to involve b-arrestins. To
further support this mechanism, we used the bARKct, a peptide
inhibitor of GRK2 activation via Gbg sequestration36. bARKct
expression reduced the activation of ERK by both MR and AT1R
(Supplementary Fig. 1a).
Critical role for GRK2 in MR-mediated myocardial pathology.
Since the above data clearly show a myocyte MR-signalling
dependence on AT1R and implicates GRK2 in this mechanism,
we next examined whether this receptor cross-talk is involved in
aldosterone-medtiated pathology in myocytes and its potential
downstream signal transduction. We examined a NOX4-depen-
dent ROS mechanism as a potential inducer of deleterious
myocyte effects of aldosterone since that appears important in HF
pathogenesis13,14,37,38. We found induction of NOX4 expression
after aldosterone treatment of myocytes and this was blocked by
both spironolactone and losartan (Fig. 2a). Aldosterone-mediated
NOX4 upregulation was also blocked by bARKct expression
(Supplementary Fig. 1b). Next, we assessed ROS formation in
myocytes using MitoSOX Red as an indicator of NOX4 activity
since it can detect superoxide production. As shown in Fig. 2b,
aldosterone (30min of exposure) increased mitochondrial ROS
generation and this was blocked by antagonizing both the MR
and AT1R as well as GRK2 via the bARKct. Further, we observed
increased mitochondrial dysfunction, in response to 24 h of
aldosterone using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay and, this was blocked by
MR and AT1R antagonism and also by GRK2 inhibition (Fig. 2c).
Importantly, treatment of myocytes with aldosterone (24 h)
induced a signiﬁcant apoptotic response that was MR, AT1R
and GRK2 dependent (Fig. 2d), consistent with the above
signalling mechanisms.
Since bARKct could block aldosterone-mediated NOX4
induction, ROS generation and myocyte apoptosis, we explored
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whether GRK2 played a direct role in this MR-dependent
pathological signalling. Interestingly, we found that aldosterone
treatment of myocytes for 12 h causes signiﬁcant upregulation of
GRK2 that was dependent on both MR and AT1R activation
(Fig. 2e). To link GRK2 induction to aldosterone-mediated
myocyte pathology, we overexpressed GRK2 in NRVMs and
examined apoptosis, which we found to be signiﬁcantly enhanced
with GRK2 overexpression (Fig. 3a). Aldosterone can also induce
hypertrophy of cardiomyocytes9 and thus, we also examined this
pathological stress condition. Indeed, in control NRVMs treated
with Ad encoding the green ﬂuorescent protein (Ad-GFP),
aldosterone induced increased cell size, as expected, however,
unlike enhancement of apoptosis with Ad-GRK2 treatment,
overexpression of GRK2 had no effect on cardiomyocyte
hypertrophy in response to aldosterone (Fig. 3b).
The above data suggest that GRK2, downstream of MR
activation, speciﬁcally regulates aldosterone-mediated ROS and
cell death signalling. To better assess the absolute requirement of
GRK2 in mitochondrial dysfunction and ROS generation, we
treated cultured NRVMs with siRNA against GRK2 and as shown
in Supplementary Fig. 2a,b, speciﬁc GRK2 silencing abolished the
effects of aldosterone on ROS generation.
In this regard, our laboratory has shown that secondarily to
ROS generation, GRK2 becomes phosphorylated by ERK at
Ser670 (S670) and this causes mitochondrial localization that is
dependent on the chaperone, heart shock 90 (Hsp90) protein,
leading to an induction of myocyte apoptosis29. Accordingly, we
investigated S670 phosphorylation (pS670) of GRK2 following
aldosterone treatment and found that MR activation leads
to GRK2 phosphorylation that is ERK dependent (Fig. 3c;
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Figure 1 | Aldosterone-mediated cross-talk between the MR and the AT1R. (a) Representative immunoblots (upper panels) and densitometric
quantitative analysis (lower panel) of multiple (n¼ 3) independent experiments to evaluate ERK 1/2 phosphorylation (pERK) as a ratio of activated ERK to
total ERK (tERK) in neonatal rat ventricular myocytes (NRVMs) either unstimulated (Ns) or stimulated with aldosterone (Aldo 1 mM) for 15min. Before
Aldo treatment, myocytes were pre-treated with spironolactone (Spiro 10mM) or losartan (Los 10mM) for 30min; *Po0.05 versus Ns. (b) Representative
immunoblots (upper panels) and densitometric quantitative analysis (lower panel) of multiple (n¼ 3) independent experiments to evaluate b-arrestin
membrane recruitment in crude plasma membrane preparations from NRVMs. Shown is a time course (0–30min) of Aldo (1mM) treatment alone or with
30min pre-treatment with Los (10mM). b-ACTIN was used as loading control; *Po0.05 versus Ns. (c) Representative immunoblots (upper panels) and
densitometric analysis (lower panel) of multiple (n¼ 3) independent experiments to evaluate pERK in NRVMs Ns or stimulated with Aldo (1 mM) for 15min.
Before Aldo, a group of cells was pre-treated with PP2 (10 mM) for 30min. tERKwas used as loading control; *Po0.05 versus Ns. (d) Representative panels
(upper panels) and densitometric analysis (lower panel) of multiple (n¼ 3) independent experiments of Co-IP assay in total lysates from NRVMs infected
with HA-tagged AT1R. Cells were Ns or stimulated with Aldo (1 mM) for 30min. Before stimulation, a group of cells was pre-treated with the c-Src
inhibitor PP2 (10mM). Immunoprecipitated proteins (IP) for HA-tag were blotted with an antibody anti-b-arrestin 1/2 antibody; *Po0.05 versus Ns.
(e) Representative immunoﬂuorescence images of NRVMs infected with HA-tagged AT1R (red, lower panels). DAPI-stained myocyte nuclei are shown in
the upper panel of images. Shown are cells treated for 30min with Aldo (1mM) or AngII (1mM) or before Aldo, pre-treated for 30min with Spiro (10 mM),
Los (10mM) or PP2 (10mM). Arrows indicate receptors that are internalized. Scale bar, 20mm. (a–d) Statistical signiﬁcance between groups was
determined by one-way ANOVA with Bonferroni post hoc correction. All data are shown as mean±s.e.m.
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Supplementary Fig. 2c). To assess whether the aldosterone-
MR-ERK signalling axis could induce GRK2 translocation to
mitochondria, we puriﬁed mitochondrial fractions from NRVMs
treated with aldosterone and found signiﬁcant mitochondrial
GRK2 accumulation (Fig. 3d). Interestingly, blocking MR
activation or AT1R activation inhibited mitochondrial
translocation of GRK2 (Fig. 3d). To establish the role of GRK2
phosphorylation on ROS generation, we analysed the effects of
elevated wild-type (WT) GRK2 in NRVMs versus a mutant
GRK2 at Ser670 (GRK2-S670A) that cannot translocate to the
mitochondria (Fig. 3e,f). As expected, following aldosterone
treatment, WT GRK2 accumulated in mitochondria (Fig. 3e,f)
and this was accompanied to an augmented ROS generation
(Fig. 3g). Importantly, when GRK2 cannot be phosphorylated at
S670, aldosterone did not lead to mitochondrial translocation of
GRK2 and subsequent ROS generation was suppressed (Fig. 3g).
Previously, the ROS-, ERK- and Hsp90-dependent mitochon-
drial targeting of GRK2 was found to be inhibited by bARKct,
since this peptide also contains S670 and ERK phosphorylation of
bARKct, which competes with endogenous GRK2 for
Hsp90 binding29. We found that aldosterone-mediated GRK2
mitochondrial translocation also appears consistent with this
model as bARKct expression blocked aldosterone-mediated
mitochondrial GRK2 accumulation (Supplementary Fig. 2d).
As expected, bARKct expression did not inhibit mitochon-
drial translocation of Hsp90 downstream of aldosterone
(Supplementary Fig. 2d). Further, we found that this
intracellular targeting of GRK2 is dependent on the actions of
AT1R transactivation-mediated b-arrestin function, since
knockdown of b-arrestin 1/2 in NRVMs abolished GRK2
mitochondrial accumulation after aldosterone stimulation
(Supplementary Fig. 2e).
Our data above suggest that aldosterone through a MR-AT1R-
dependent pathway, induces a rapid response that increases ERK
with a consequent increase in ROS generation. However, previous
reports have shown that aldosterone can directly activate the
oestrogen receptor (GPER) that is responsible for the rapid
ERK activation observed following aldosterone stimulation39.
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Figure 2 | Aldosterone induced oxidative stress and apoptosis. (a) Representative immunoblots (upper) and densitometric quantitative analysis (lower)
of panels of multiple (n¼ 3) independent experiments to evaluate NOX4 protein levels in NRVMs unstimulated (Ns) or stimulated with Aldo (1mM) for
15min. Before Aldo, a group of cells was pre-treated with Spiro (10mM) or Los (10 mM) for 30min. GAPDH was used as loading control; *Po0.05 versus
Ns. (b) Representative panels (upper) and cumulative ﬂuorescence data (bottom) from (n¼ 3) independent experiments of MitoSOX Red staining of
NRVMs (B200 cells analysed for the group for each experiment) infected with adenoviruses encoding for either GFP or bARKct. Myocytes were then Ns
or stimulated for 30min with Aldo. Before Aldo stimulation, a group of GFP cells was pre-treated (30min) with Spiro (10mM) or Los (10 mM); *Po0.05
versus GFP Ns. Scale bar, 50mm. (c) Bar graphs showing multiple (n¼ 3) independent experiment of MTTassay using NRVMs expressing bARKct or GFP
after Aldo treatment for 24 h. Before Aldo stimulation, a group of GFP cells was pre-treated with Spiro (10 mM) or Los (10 mM) for 30min; *Po0.05 versus
GFP Ns. (d) Representative panels of TUNEL-positive myocytes (Red staining with blue DAPI staining) and quantitative data (n¼ 3 independent
experiments) showing NRVM apoptosis (B1,000 cells analysed for the group for each experiment) induced by Aldo (1 mM for 24 h) with Ad-GFP infection
or Ad-bARKct treatment. Before Aldo stimulation, a group of GFP cells was pre-treated with Spiro (10 mM) or Los (10 mM) for 30min; scale bar, 200mm.
*Po0.05 versus GFP Ns. (e) Representative immunoblots (upper panels) and densitometric quantitative analysis (lower panel) of multiple (n¼ 3)
independent experiments to evaluate GRK2 protein levels in NRVMs Ns or stimulated with Aldo (1mM) for 12 h. Before Aldo, a group of cells was pre-
treated with Spiro (10mM) or Los (10 mM) for 30min. GAPDH was used as loading control. *Po0.05 versus Ns. (a–e) Statistical signiﬁcance between
groups was determined by one-way ANOVA with Bonferroni post hoc correction. All data are shown as mean±s.e.m.
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To clarify whether aldosterone effects in myocytes are due to a
GPER or MR-AT1R pathway, we used the GPER agonist E2 and
the GPER antagonist G36. As expected, E2 stimulation resulted in
a signiﬁcant ERK activation that was efﬁciently blocked by G36
(Supplementary Fig. 3a). Notably, pre-treatment of cells with G36
resulted in a signiﬁcant but incomplete inhibition of aldosterone-
mediated ERK phosphorylation that was much less effective at
blocking aldosterone signalling compared to spironolactone and
losartan suggests that GPERs can be modestly involved in acute
ERK activation mediated by aldosterone (Supplementary Fig. 3b).
Since a recent report has shown that genetic silencing of GPER
further increased aldosterone-induced ROS production with
mechanisms that may suggest GPER-dependent inhibition of
deleterious AT1R or MR signalling40, we explored the effects of
GPER activation/inhibition on aldosterone-dependent GRK2
phosphorylation and ROS generation. Surprisingly, we found
that E2 treatment of NRVMs resulted in a consistent reduction of
basal phosphorylation of GRK2, at S670, that was restored by G36
(Supplementary Fig. 3c). Most importantly, we found that
GPER inhibition did not affect aldosterone-dependent GRK2
phosphorylation (Supplementary Fig. 3d). In line with these
results, we found that GPER activation was not able to increase
ROS generation, and its inhibition with G36 also did not affect
aldosterone-dependent ROS generation (Supplementary Fig. 3e).
However, treatment of cells with both E2 and aldosterone resulted
in an impaired cardiotoxicity compared to aldosterone alone-
treated cells (Supplementary Fig. 3e). Taken together, these data
suggest that GPER activation downstream of high aldosterone
are not a major player in myocyte pathology as previously
suggested39, and it appears to be due to MR-AT1R signalling.
GRK5 is a regulator of MR/AT1R-mediated cardiomyocyte
hypertrophy. The above results show that, although GRK2’s non-
canonical actions on mitochondrial-mediated cell death appear
activated by MR-AT1R signalling, there was no effect on cardiac
hypertrophy, prompted us to investigate another GRK involved in
myocardial pathology, GRK5. The role of GRK5 in maladaptive
hypertrophy has been shown to also entail non-canonical activity
as a class II histone deacetylase (HDAC) kinase and nuclear factor
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Figure 3 | Aldosterone-mediated GRK2 mitochondrial localization in myocytes. (a,b) Representative images and quantitative data from (n¼ 3)
independent experiments showing (a) apoptotic (TUNEL staining; scale bar, 100mm) NRVMs (B1,000 cells analysed for the group for each experiment) or
(b) hypertrophic (a-sarcomeric actin staining; scale bar, 50mm) NRVMs (B200 cells analysed for the group for each experiment) infected with either
Ad-GFP or Ad-GRK2 to determine the effect of Aldo with GRK2 overexpression. Myocytes were unstimulated (Ns) or stimulated with Aldo (1mM) for
24 (a) or 48 h (b). *Po0.05 versus GFP Ns; #Po0.05 versus GFP Aldo. (c) Representative immunoblots (upper panels) and densitometric quantitative
analysis (lower panel) of multiple (n¼ 3) independent experiments to evaluate GRK2 phosphorylation (ser670) or ERK 1/2 phosphorylation (pERK) levels
in NRVMs Ns or stimulated with Aldo (1 mM) for 15min. Before Aldo, a group of cells was pre-treated with U0126 (3 mM) for 30min. Total ERK (tERK) and
GRK2 are shown as loading controls; *Po0.05 versus Ns. (d) Representative immunoblots (upper panels) and densitometric quantitative analysis (lower
panel) of multiple (n¼ 3) independent experiments to evaluate GRK2 levels in mitochondrial fractions puriﬁed from NRVMs that were either Ns or
stimulated with Aldo (1 mM) for 30min. Before Aldo, a group of cells was pre-treated with Spiro (10 mM) or Los (10mM) for 30min. VDAC was used as
loading and mitochondrial purity control; *Po0.05 versus Ns. (e,f) Representative immunoblots (e) and denistometric quantitative analysis (f) of multiple
(n¼ 3) independent experiments to evaluate GRK2 levels in mitochondrial fractions puriﬁed from NRVMs infected with Ad-GRK2 and Ad-GRK2-S670A
that were either Ns or stimulated with Aldo (1mM) for 30min. VDAC was used as loading and mitochondrial purity control; *Po0.05 versus GRK2 Ns. (g)
Cumulative ﬂuorescence data from (n¼ 3) independent experiments of MitoSOX Red staining of NRVMs (B200 cells analysed for the group for each
experiment) infected with adenoviruses encoding for either GRK2 or GRK2-S670A. Myocytes were then Ns or stimulated for 30min with Aldo. *Po0.05
versus GRK2 Ns; #Po0.05 versus GRK2 Aldo. (a–d,f,g) Statistical signiﬁcance between groups was determined by one-way ANOVA with Bonferroni post
hoc correction. All data are shown as mean±s.e.m.
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of activated T-cells (NFAT) activator/co-factor where increased
nuclear accumulation of GRK5 induces pathological gene tran-
scription27,31,41. In fact, AngII, which is a potent inducer of
myocardial hypertrophy, can induce GRK5 translocation to the
nucleus and interestingly, the AT1R is not a target of GRK5-
mediated desensitization27. Importantly, it has been previously
shown that high-aldosterone levels can increase, in the heart,
transcription of the myocyte enhancer factor-2 (MEF2) through
the activation of Ca2þ /calmodulin kinase II (CAMKII)13. Further,
aldosterone can activate the calcineurin-NFAT pathway, in an
AT1R-dependent manner42. Notably, these mechanisms are similar
to the proposed model of pathological cardiac hypertrophy
induced by the AT1R that is dependent on GRK5 (ref. 27). To
test the hypothesis that aldosterone might induce this nuclear
activity of GRK5, we ﬁrst looked at NRVMs and found that
aldosterone was indeed an inducer of GRK5’s nuclear
accumulation similar to AngII (Fig. 4a). Moreover, in adult
murine ventricular myocytes we found similar induction of nuclear
translocation of GRK5 via immunoﬂuorescence (Fig. 4b). GRK5’s
nuclear localization after aldosterone was blocked by
spironolactone treatment as well as losartan (Fig. 4c).
Furthermore, we analysed the effects of GRK5 nuclear
localization on MEF2 activation, and as shown in Fig. 4d, we
found that in the presence of aldosterone MEF2 transcriptional
activity was signiﬁcantly increased compared to unstimulated cells.
This increase was completely abolished by pre-treatment of cells
with spironolactone and losartan (Fig. 4d). Moreover, through a
GRK5 knockdown assay (Fig. 4e), we conﬁrmed the absolute
requirement of GRK5 in MEF2 activation (Fig. 4f) and in cardiac
hypertrophy (Fig. 4g) downstream of aldosterone. Consistent with
this, we found that overexpression of GRK5 enhanced NRVM cell
size after 48 h of aldosterone treatment compared to the normal
hypertrophy induced by aldosterone treatment without elevated
GRK5 levels (GFP-control cells; Fig. 5a).
To better deﬁne the role of GRK5 and its nuclear activity being
involved in aldosterone-mediated myocyte hypertrophy, we
tested outcomes of elevated WT GRK5 versus overexpression
of a mutant GRK5 lacking its nuclear localization signal
(GRK5-DNLS). As expected, we observed that aldosterone
treatment of myocytes induced consistent GRK5 nuclear
localization with a robust increase in cell size growth
(Fig. 5b–d). However, when GRK5-DNLS was overexpressed,
there was no nuclear GRK5 localization and signiﬁcantly
diminished aldosterone-dependent cardiac hypertrophy (Fig. 5b–d).
To better evaluate the speciﬁc mechanism involved in
MR-AT1R-dependent GRK5 nuclear translocation, we explored
G
RK
5/
fib
ril
la
rin
 n
uc
le
ar
le
ve
ls
 (fo
ld 
ov
er 
Ns
)
M
EF
-2
 p
ro
m
ot
er
lu
ci
fe
ra
se
 (R
FU
)
M
EF
-2
 p
ro
m
ot
er
lu
ci
fe
ra
se
 (R
FU
)
Ce
ll s
ize
 (a
.u.
)
2
IB: GRK5
Nuclei
64
50
1.5
1
0.5
0
15,000
5,000
1,000
800
*
600
400
200
0
4,000
3,000
2,000
1,000
0
10,000
5,000
0
Ns Ald
o
Sp
iro
/Al
do
Lo
s/A
ldo
Ald
o
Sp
iro
/Al
do
Lo
s/A
ldo
Ns Aldo AngII
IB: fibrillarin
IB: FIBRILLARIN
Ab
-G
RK
5
D
AP
I
*
*
*
Ns
Ns NsAldo Aldo
siGRK5
siGRK5
IB: GRK56450
36
siScr
siScr
Ns NsAldo Aldo
siGRK5siScr
a b c
d
e
g
f
2
64
50
1.5
G
RK
5/
fib
ril
la
rin
 n
uc
le
ar
le
ve
ls
 (fo
ld 
ov
er 
Ns
)
1
0.5
0
NS Aldo AngII
IB: GRK5
*
*
IB: fibrillarin
Nuclei
AngIIAldoNs
Figure 4 | Aldosterone-mediated GRK5 nuclear localization and hypertrophic response. (a) Representative immunoblots (upper panels) and
densitometric analysis (lower panel) of multiple independent experiments (n¼ 3) to evaluate GRK5 levels in nuclear fractions puriﬁed from NRVMs,
unstimulated (Ns) or stimulated with Aldo (1 mM) or AngII (1mM) for 30min. Fibrillarin was used as loading control; *Po0.05 versus Ns.
(b) Representative panels of DAPI (upper) and GRK5 (bottom) immunoﬂuorescence images in adult ventricular myocytes. The cells were Ns or stimulated
with Aldo (1mM) or AngII (1mM) for 30min; scale bar, 10mm. (c) Representative immunoblots (upper panels) and densitometric analysis (lower panel) of
multiple independent experiments (n¼ 3) to evaluate GRK5 levels in nuclear fractions puriﬁed from NRVMs Ns or stimulated with Aldo (1 mM) for 30min.
Before Aldo, a group of cells was pre-treated with Spiro (10 mM) or Los (10 mM) for 30min. Fibrillarin was used as loading control; *Po0.05 versus Ns.
(d) Bar graph showing MEF2 reporter activity in NRVMs measured using a luciferase assay system. Cells were infected with an Ad encoding for MEF2
promoter-luciferase (Ad-MEF2-Luc) reporter construct for 48 h. Following the infection, the cells were Ns or stimulated for 24 h with Aldo (1mM). Before
Aldo, a group of cells was pre-treated with Spiro (10 mM) or Los (10mM) for 30min; *Po0.05 versus Ns. (e) Representative immunoblots showing total
GRK5 levels in NRVMs transfected with siRNAs targeting GRK5 (siGRK5). Scrambled siRNAs (siScr) were used as control. The cells were then Ns or
stimulated for 24 h with Aldo (1 mM). (f) Bar graph showing MEF2 reporter activity in NRVMs measured using a luciferase assay system. Cells were
infected with an Ad-MEF2-Luc and transfected with siRNAs targeting GRK5 (siGRK5). siScr were used as control. The cells were then Ns or stimulated for
24 h with Aldo (1mM); *Po0.05 versus siScr. (g) Cumulative ﬂuorescence data from (n¼ 3) independent experiments of a-sarcomeric actinin staining in
NRVMs (B200 cells analysed for the group for each experiment) transfected with siGRK5 or siScr. The cells were Ns or stimulated with Aldo (1mM) for
48 h; *Po0.05 versus siScr Ns. (a,c,d,f,g) Statistical signiﬁcance between groups was determined by one-way ANOVA with Bonferroni post hoc correction.
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the ability of b-arrestin recruitment to inﬂuence the nuclear
translocation of GRK5. Interstingly, we found that knockdown of
b-arrestin 1/2 abolished GRK5 nuclear translocation downstream
of aldosterone (Supplementary Fig. 4a). Finally, we explored the
ability of aldosterone to induce the activation of Ca2þ -
calmodulin (CaM) that previously has been shown to be the
nodal regulator of AngII-mediated GRK5-nuclear accumula-
tion31. We pre-treated NRVMs with losartan, to inhibit the AT1R,
and we stimulated the cells with aldosterone. Following this,
we performed a Co-IP assay between GRK5 and CaM and
importantly, we observed that while aldosterone induced a
signiﬁcant increase in CaM binding to GRK5, this was blocked by
losartan (Supplementary Fig. 4b).
In vivo effects of aldosterone are mediated by GRK2 and
GRK5. After MI in humans, plasma aldosterone concentrations
are robustly increased43 and the augmented concentration of this
hormone can negatively affect cardiac function and HF
progression13. To determine if any of the above in vitro results
translate in vivo, we administered aldosterone to mice for 4 weeks
to create a state of hyper-aldosteronism. Following chronic
administration of aldosterone (2 mg per day for 4 weeks) via
mini-osmotic pumps implanted subcutaneously, serum aldosterone
levels were similar to the endogenous upregulation of this
hormone observed in the blood serum of post-MI mice at 4 weeks
(Supplementary Fig. 5a), which is consistent with reports in the
literature2,13,43,44 of a B2-fold increase after MI, including in
humans.
We assessed the effects of 4 weeks of aldosterone treatment on
murine cardiac function. As shown in Table 1, aldosterone
induced signiﬁcant pathology indicated by ventricular dysfunc-
tion and adverse remodelling, including cardiac hypertrophy.
At the tissue level, we found increased cardiac apoptosis, as
shown by terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) staining (Fig. 6a), and increased
myocardial ﬁbrosis as assessed by Picro-Sirius red staining
(Fig. 6b) in mice treated for 4 weeks with aldosterone. Consistent
with the signiﬁcant ventricular dysfunction observed in aldoster-
one-treated mice, GRK2 and GRK5 were upregulated in the heart
(Fig. 6c,d). Interestingly, the in vivo increases in both GRKs,
induced by aldosterone, resulted in the enhancement of their
non-canonical pathological cellular locations as these hearts
showed signiﬁcantly more GRK2 localized to mitochondria
(Fig. 6e) and signiﬁcant GRK5 accumulation in nuclear fractions
(Fig. 6f).
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To determine the absolute requirement of GRK2 and GRK5
on the pathological myocardial effects of chronic hyper-
aldosteronism, we used conditional Grk2 and Grk5 knockout
(KO) mice where these kinases were deleted speciﬁcally in
cardiomyocytes29,31,45. Control mice (ﬂoxed alleles alone), or
cardiac Grk2 KO or Grk5 KO mice were treated as above for 4
weeks with aldosterone and we serially assessed their cardiac
function with echocardiography. We also included aMHC-Cre
alone mice as an additional control for Cre expression in the heart
for these experiments. Impaired cardiac function (EF) and
increased left ventricular diameter (LVIDd) were similarly
altered in control mice (including aMHC-Cre alone mice;
Supplementary Fig. 5b,c) consistent with the above results after
4 weeks of hyper-aldosteronism. However, these effects were
completely prevented by the loss of GRK2 in myocytes and in
part attenuated by the lack of GRK5 in cardiomyocytes
(Fig. 7a,b). Of interest, posterior wall (PW) thickness, a marker
of ventricular growth, was increased by aldosterone in both
controls and Grk2 KO mice (Fig. 7c). However, consistent with
the role of GRK5 (in the nucleus) in pathological cardiac
hypertrophy, no PW increase was observed in Grk5 KO mice
(Fig. 7c). To further examine mechanisms of aldosterone-
mediated cardiac dysfunction, we analysed cardiac hypertrophy
via heart weight and found that indeed after 4 weeks of
aldosterone infusion there was signiﬁcant cardiac hypertrophy
as measured by heart weight to body weight (HW/BW) ratios
with control mice have the largest hearts (Fig. 7d). Of note,
both Grk2 KO and Grk5 KO had only slight increases in
HW/BW ratios after 4 weeks of aldosterone compared to controls
(Fig. 7d).
Table 1 | Effect of aldosterone treatment on LV function
evaluated by echocardiography at 4 weeks after minipump
implantation in WT mice.
WT C57BL/5 N¼6 N¼6
4 Weeks Vehicle Aldosterone
EF (%) 58.1±4 42±4.1*
FS (%) 30.4±2.5 22.6±4*
LVIDd 3.5±0.14 3.94±0.18*
LVIDs 2.5±0.22 2.78±0.3
PWd 0.52±0.04 0.85±0.04*
PWs 0.76±0.05 1.1±0.06*
HR 415±17.1 425±21.6
HW/BW 5.5±0.2 6.4±0.2*
In vivo ejection fraction (EF) and fractional shortening (FS) percentage, LV internal diameter
at diastole (LVIDd), LV internal diameter at systole (LVIDs), posterior wall diastolic thickness
(PWd), PW systolic thickness (PWs) and heart rate (HR) were assessed in wild-type (WT) mice
(vehicle versus aldosterone). Ratio of heart weight to body weight (HW/BW) was also
measured in all groups. All data are shown as mean±seem. Statistical signiﬁcance between
groups was determined by Mann-Whitney exact test. N¼6 mice for each group.
*Po0.05 versus vehicle.
TUNEL/DAPI
Ve
h
Ve
h
Picro-sirius red
Veh
Total lysates
Veh Aldo
Total lysates Mitochondria
Nuclei
Veh Aldo
Veh VehAldo Aldo
98
2
G
RK
2/
G
AP
DH
le
ve
ls
(fo
ld 
ov
er 
NS
)
1.5
1
0.5
0
2.5
2
G
RK
5/
G
AP
DH
le
ve
ls
(fo
ld 
ov
er 
NS
)
G
RK
2/
VD
AC
 m
ito
le
ve
ls
(fo
ld 
ov
er 
NS
)
G
RK
5/
LA
M
IN
 A
/C
n
u
cl
ea
r l
ev
el
s
(fo
ld 
ov
er 
NS
)
1.5
1
0.5
0
2
1.5
1
0.5
0
2
1.5
1
0.5
0
2.5
Veh Aldo Veh Aldo Veh Aldo Veh Aldo
*
*
*
*
36
64 98
64
98
64
98
30
36
IB: GRK2 IB: GRK5
IB: HSP90
IB: GRK2
IB: GRK5
IB: LAMIN A/C
IB: VDACIB: GAPDH
IB: GAPDH
Veh
* *
TU
NE
L-
po
sit
ive
 n
uc
le
i
(%
)
0.25 25
2
1.5
1
0.5
0
0.2
Fi
br
os
is 
(%
)
0.15
0.1
0.05
0
Al
do
Al
do
Aldo Aldo
a b
c d e f
Figure 6 | In vivo effects of chronic aldosterone treatment on murine myocardium. (a,b) Representative images and quantitative data from mice treated
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(c) and GRK5 (d) protein levels in total cardiac lysates from mice treated with Aldo or Veh for 4 weeks; *Po0.05 versus Veh. (e) Representative
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test. All data are shown as mean±s.e.m.
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To explain the differences observed between PW thickness
with loss of expression of GRK2 or GRK5 in myocytes, we
evaluated the effects of aldosterone on cardiac apoptosis and
ﬁbrosis. Consistent with the above results, chronic hyper-
aldosteronism caused signiﬁcant cardiac apoptosis and ﬁbrosis
in control mice (Fig. 8a–d) and the loss of GRK2 or GRK5
signiﬁcantly affected this; however, the loss of GRK2 was
signiﬁcantly more effective at attenuating myocyte death and
replacement ﬁbrosis compared to the loss of GRK5 (Fig. 8a–d).
As a further proof of this GRK-selective mechanism, we analysed
the expression of connective tissue growth factor (CTGF), a
surrogate marker of pro-ﬁbrosis shown to be modulated directly
by MR46. Indeed, in the hearts of aldosterone-treated control
mice there was robust upregulation of Ctgf mRNA (Fig. 8e). In
cardiac Grk2 KO mice, there was no Ctgf induction while a
signiﬁcant but smaller reduction was observed when GRK5 was
deleted in cardiomyocytes compared to control mice (Fig. 8e).
These results are consistent with GRK2 being selectively involved
in the ﬁbrotic response induced by aldosterone via mitochondrial
cell death, while GRK5 appears signiﬁcantly involved in the
hypertrophic mechanisms of pathology induced by this hormone,
that is, translationally signiﬁcant since both GRKs have been
shown to be upregulated in human HF23,24,45,47.
To further explore the speciﬁc role of GRK2 and GRK5 in the
aldosterone-dependent ﬁbrotic response, we analysed the effects
in vitro, in NRVMs, of the overexpression of GRK2 and GRK5 on
Ctgf expression. Importantly, we found in control myocytes
that aldosterone induced signiﬁcant upregulation of CTGF
(Supplementary Fig. 6a). Interestingly, GRK5 overexpression
had no effect on aldosterone-mediated CTGF upregulation but
GRK2 overexpression signiﬁcantly enhanced this response
(Supplementary Fig. 6a). Consistent with GRK2 being nodal in
the ﬁbrotic response of aldosterone in myocytes, we took
conditional media from aldosterone-treated myocytes and found
that the media from GRK2 overexpressing myocytes signiﬁcantly
enhanced the migration of cultured cardiac ﬁbroblasts more than
cultured media of control (Ad-GFP) and GRK5 overexpressing
myocytes (Supplementary Fig. 6b).
These data strongly suggest that aldosterone-mediated
activation of GRK2 increases the secretion of the stress-induced
factor CTGF from cardiomyocytes that then acts as a paracrine
factor that enhances the activation of cardiac ﬁbroblasts
contributing to ﬁbrosis.
Finally, since we have observed that spironolactone treatment
blocked the aldosterone-mediated upregulation of GRK2 in
myocytes (Fig. 2e), we investigated whether MR-antagonist-
treated human HF patients had altered GRK2 levels in peripheral
lymphocytes. Importantly, lymphocyte GRK2 levels have been
shown to mirror levels in failing human myocardium and
negatively correlating with haemodynamic function23,24.
Accordingly, we analysed, by immunoblot, lymphocyte GRK2
levels in human HF patients treated with spironolactone and
compared these levels to a cohort of similarly diseased patients
where the MR-antagonist was not used (Supplementary Table 1).
Interestingly, patients treated with the MR-blocker had
signiﬁcantly lower GRK2 levels (Supplementary Fig. 7)
consistent with this pathway having a pathophysiological
inﬂuence on myocardial GRK2 levels and activity.
Discussion
It is well known that a primary pathogenic driver of cardiac
dysfunction and HF is hyper-activation of neurohormonal
signalling, which propagates and maintains a vicious cycle of
injury. This involves chronic sympathetic nervous system
activation through increased catecholamines and also enhanced
RAAS activation2. The catecholamines, norepinephrine and
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epinephrine, chronically stimulate b-adrenergic receptors (bARs)
on cardiomyocytes while the RAAS promotes chronic AT1R
activation via AngII and enhanced hyper-aldosteronism that
leads to chronic MR activation. Adding to the importance of
these systems and their hyper-activation, agents that block the
chronic stimulation of these receptors are part of the current
standard of care of HF patients, including MR antagonists.
However, not all patients beneﬁt from these drugs and new and
innovative strategies for treating HF are desperately needed.
Accordingly, a deeper understanding of the molecular
mechanisms contributing to HF development and progression
represents the best case scenario for ﬁnding new therapeutics.
In this study, we have uncovered that GRK2 and GRK5 are
critical molecules downstream of aldosterone and MR activation.
In fact, they appear to be nodally involved in MR-mediated
cardiac pathology as loss of GRK2 and GRK5 in myocytes
signiﬁcantly alleviates cardiac dysfunction due to hyper-
aldosteronism.
Our data clearly indicate that some of the pathological effects
of the aldosterone are not mediated solely on MR activation, but
are dependent on the transactivation of AT1R. We found that
aldosterone treatment elicited a robust apoptotic, ﬁbrotic and
hypertrophic response in myocytes and these effects were
completely abolished by selective MR- or AT1R-antagonism,
in vitro (Figs 2–4). At the molecular level, we observed that
following aldosterone-MR binding that speciﬁc GPCR-dependent
endocytic machinery is recruited (Gbg/b-arrestin/c-Src) at the
plasma membrane leading to AT1R internalization and to the
activation of ERK 1/2 and NOX4. This increase in ROS formation
consequently can cause myocardial dysfunction via mitochondrial
superoxide formation and a robust apoptotic response. Impor-
tantly, our data clearly show that GRK2 is vital to this response
mainly through its non-canonical mitochondrial localization,
which appears nodally involved in the ‘non-genomic’ actions of
aldosterone (Fig. 9).
In addition to GRK2 being involved in aldosterone-dependent
pathology, we found that MR-AT1R activation leads to the
nuclear translocation of GRK5, thus explaining in part the
mechanism of aldosterone-mediated hypertrophic response in
cardiomyocytes where this non-canonical action of GRK5
contributes to the ‘genomic’ pathway of aldosterone-mediated
pathology (Fig. 9).
Importantly, we also evaluated the role of the GPER that has
been widely associated to the non-genomic role of aldosterone in
non-myocytes and recently also in an in vitro model of
cardiomyocytes (H9c2) (ref. 39). H9c2 cells are skeletal muscle
myoblasts and although they are widely used as a surrogate of
cardiomyocytes they have properties that complicate the state of
MR signalling, including demonstration that H9c2 cells lose
functional MRs and exhibit very low levels of aldosterone-speciﬁc
MR-binding51. Interestingly, in H9c2 cells the GPER was found
to play an important role in aldosterone-mediated deleterious
signalling that could be crucial in human HF39.
Our data, in NRVMs show that high-aldosterone levels can
activate GPER signalling but this receptor appears to have a
minimal effect on myocardial pathology induced by aldosterone
that instead is suggested to be fully mediated by AT1R-MR
signalling.
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Importantly, we uncovered in myocytes that aldosterone-
dependent GPER activity does not explain induction of
pathology, which is consistent with previous reports39,52,
including in vascular smooth muscle cells where GPER
stimulation can protect against hyper-activation of the MR52.
The most notable ﬁndings of our study were that the
aldosterone-mediated negative effects on mitochondrial super-
oxide formation, myocyte cell death and hypertrophy were all
attenuated by MR blockade with spironolactone or AT1R
antagonism with losartan and limited aldosterone’s actions by
reducing the non-canonical activities of GRK2 and GRK5. Similar
effects were seen using the most selective MR-antagonist
eplerenone and the AT1R antagonist irbesartan (Supplementary
Fig. 8a–c). Our data appear to be relevant to human HF as
we found patients, treated with a protocol that included
spironolactone, had signiﬁcantly lower GRK2 levels in white
blood cells, which previously has been shown to mirror cardiac
levels23,24. However, although these data need more investigation,
they strongly suggest that GRK2 lowering in the myocardium and
lymphocytes can be associated with improved cardiac function, as
previously described24,48.
Of note, previous studies have already linked GRK2 and GRK5
to HF development20,21,27,31, but, our data demonstrate for the
ﬁrst time that GRK2 and GRK5, acting downstream of MR
activation, can induce speciﬁc myocardial pathologies. We
demonstrate in vivo that 4 weeks of aldosterone represent a
trigger stimulus for GRK2 and GRK5 upregulation and the
above-discussed, non-canonical activities. These activities of
GRKs appear to be signiﬁcantly relevant for aldosterone-
mediated HF, since cardiac Grk2 and Grk5 KO mice have
ameliorated myocardial dysfunction. The importance of
GRK-mediated cardiac pathology following chronic hyper-
aldosteronism is surprising since GRKs do not regulate MR
signalling. However, with the ﬁnding that MR activation
transactivates AT1Rs in myocytes there is still a potential GPCR
dependence to these pathological actions of GRK2 and GRK5.
These results also demonstrate that limiting MR activation can
reduce these pathological actions.
Importantly, we observed that although GRK2 clearly is a
nodal determinant of aldosterone-mediated myocyte death and
ultimately ﬁbrosis in vivo, this kinase did not inﬂuence
aldosterone-mediated cardiac hypertrophy, which is also a
pathological feature of hyper-aldosteronism8,9. This is an
interesting ﬁnding and demonstrates that this MR-mediated
hypertrophic signalling, which also may include AT1R
transactivation, does not involve GRK2. This is in line with
previous observation since GRK2 has not been previously shown
to be important in cardiac hypertrophy49. However, GRK5
aldosterone-MR-AT1R signalling is a nodal regulator of
pathological cardiac growth in hyper-aldosteronism due to
nuclear accumulation where its recent transcriptional inﬂuence
has been revealed27,41. This was clearly shown in cardiac GRK5
KO mice where ventricular wall thickness was prevented after
hyper-aldosteronism.
Recently, He et al.13 showed that aldosterone can induce direct
cardiotoxic effects through the activation of the NADPH oxidases
and subsequent ROS generation via actions of CAMKII acting in
the nucleus after it becomes oxidized. CAMKII could become
oxidized by MR activation and AT1R activation separately, but
the co-dependence of the two receptor systems was not directly
studied as in our experiments herein where GRK2 and GRK5
appear to also be nodal regulators of the pathological effects of
aldosterone. Importantly, the mechanism proposed for CAMKII
appears to be only responsible for cardiac rupture and mortality
after MI13, which was not directly, evaluated in our study. The
authors in this study used aldosterone infusion after MI, which
raises levels to supra-physiological concentrations13 and in our
study, levels of aldosterone were equivalent to what is seen in
control mice after MI. We importantly, did not see signiﬁcant
deaths via rupture with physiological levels of aldosterone, but
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Figure 9 | Schematic representation of aldosterone-dependent activation of GRK2 and GRK5 in NRVMs. Following binding with the MR, aldosterone
recruits the b-arrestin/c-Src complex thus inducing the endocytosis of the AT1R and then leading to the activation of ‘genomic’ and ‘non-genomic’
pathways. GRK5 is part of genomic pathway since following AT1R activation, it binds to the Ca
2þ -CaM and translocates into the nucleus of the
cardiomyocyte. Then, GRK5 acts as a HDAC5 kinase increasing the transcription of hypertrophic genes (that is, MEF2). In contrast, GRK2 is mainly involved
in the non-genomic response to aldosterone stimulation. In fact, this kinase following NADPH oxidases and ERK activation is phosphorylated at ser670, and
following the binding to the chaperone HSP90, GRK2 translocates to mitochondria, where it increases myocyte apoptosis. Aldosterone through GPER
activation activates a parallel signalling that inhibits the phosphorylation of GRK2 and the subsequent ROS generation. Thus, GRK2 and GRK5 participate to
ventricular dysfunction and heart failure progression downstream of hyper-aldosteronism. Treatment of cardiomyocytes with MR or AT1R antagonists or
with bARKct and also knockdown of GRK2 or GRK5 them self inhibit the MR/AT1R signalling axis.
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signiﬁcant ventricular dysfunction and remodelling that was
beneﬁcially altered with less GRK2 and GRK5. Interestingly,
although a CamkII KO mouse was protected from rupture13, it
was not protected from ﬁbrosis, which we ﬁnd in Grk2 KO mice,
or by hypertrophy as seen in our Grk5 KO mice. Therefore, GRK
pathways and an oxidated-CAMKII pathway appear parallel and
distinct with GRK2 being a nodal regulator of aldosterone-
mediated cell death and ﬁbrosis, and GRK5 being involved in its
hypertrophic response.
Over the past two decades, GRK2 inhibition has led to
prevention or reversal of several animal models of HF20,21,
including most recently with bARKct gene therapy in a pre-
clinical large animal model of HF50. Thus, GRK2 inhibition
appears to be a novel therapeutic strategy for alleviating cardiac
dysfunction. New data are emerging, that part of the mechanism
for the beneﬁcial effects in the heart of limiting GRK2 activity
includes non-canonical roles for GRK2, including its actions on
insulin signalling28 and mitochondrial-dependent cell death29,30.
Similarly, GRK5 is also becoming an emerging novel target for its
non-canonical role in the pathological hypertrophic response.
Importantly, our present study demonstrates that GRK2
and GRK5 are primary determinants of cardiac dysfunction
downstream of hyper-aldosteronism via their non-GPCR
activities. Further, at least for GRK2, clinical treatment in
human HF with spironolactone can reduce this. Accordingly,
both these kinases are potential targets for HF therapy not only
because of pathologic activity downstream of elevated
sympathetic tone but also hyper-active RAAS signalling.
Methods
Agonists and inhibitors. Aldosterone was purchased from Sigma-Aldrich (A9477,
St. Louis, MO, USA); AngII was purchased from Sigma-Aldrich (A9525); losartan
was purchased from Sigma-Aldrich (61188); spironolactone was purchased from
Sigma-Aldrich (S3378); and PP2 was purchased from Santa Cruz Biotechnology
(sc-202769, Dallas, TX, USA). U0126 was purchased from Sigma-Aldrich (U120);
eplerenone was purchased from Sigma-Aldrich (107724-20-9); irbesartan was
purchased from Sigma-Aldrich (I2286); and PD 98059 was purchased from
Sigma-Aldrich (P215). b-Estradiol was purchased from Sigma-Aldrich (E8875)
and G36 was purchased from AzanoBiotech (AZ00004-G36, AzanoScientiﬁc,
Albuquerque, NM, USA).
Cell culture. Ventricular cardiomyocytes were isolated from 1- to 2-day-old
neonatal rat hearts (NRVMs). Hearts were pre-washed in ADS buffer (NaCl
116mmol l 1, HEPES 20mmol l 1, Na2HPO4 0.8mmol l 1, glucose
5.6mmol l 1, KCl 7mmol l 1 and MgSO4-7H2O 0.8mmol l 1, pH 7.35) to
remove blood and then divided and placed in dishes with 7ml of ADS. They were
minced with sterol razor blades in small pieces and then the whole solutions
were transferred in ﬂasks and incubated at 37 C with 7ml enzyme solution
(ADS containing pancreatin 0.6mgml 1, collagenase II 8820U l 1 and CaCl2
50mmol l 1) for 10min. The supernatant from this pre-digestion step was
discarded and the pieces were incubated with 15ml of digestion solution for
15-min intervals at 37 C. After each interval, the supernatant was collected in
50ml conical tubes containing 19ml of F-10 media and 20% FBS pre-heated at
37 C. The three to six collected fractions were spun down at 1,400g for 10min, the
supernatant was discarded and cells were washed with 5ml of FBS for each tube.
The cells were then centrifuged at 1,400g for 10min and the supernatant was
discarded. The resulting pellet containing the NRVMs was resuspendend in HAM’s
F10 complete media containing 10% horse serum (HS), 5% FBS and 1% penicilli-
streptomycin (P/S), pH 7.4. The cell suspension was ﬁltered through a 70 mm ﬁlter
and pre-plated on a Nunc Nunclon 100mm (Thermo Fisher Scientiﬁc, Waltham,
MA, USA) cell culture dish for 2 h to separate the ﬁbroblasts from the myocyte
fraction. The supernatant containing mostly myocytes was collected and plated on
culture dishes with Ham’s F-10 complete media. The ﬁbroblast attached to the
Nunclon dishes were cultured with DMEM 1 plus 1% P/S. Next the cells were
maintained in media without HS and supplemented only with 10% FBS and P/S.
Stimulation of cells with each agonist or inhibitor was performed in serum-free
media. Control unstimulated cells were maintained in serum-free media.
Adult ventricular cardiac myocytes (AVMs) were isolated from LV-free wall
and septum of C57/Bl6 mice. Mice were kept under anaesthesia with isoﬂurane and
to facilitate the perfusion they were injected with heparin 100 USP into the renal
artery. After removal from thoracic cavity, hearts were washed in cold perfusion
buffer (NaCl 120.4mmol l 1, KCl 14.7mmol l 1, KH2PO4 0.6mmol l 1,
Na2HPO4 0.6mmol l 1, MgSO4-7H2O 1.2mmol l 1, Na-HEPES 10mmol l 1,
NaHCO3 4.6mmol l 1, taurine 30mmol l 1, butanedione monoxime (BDM)
10mmol l 1 and glucose 5.5mmol l 1, pH 7.0). Followed cannulation on a
Langendorff system, they were perfused with perfusion buffer at 37 C for 2–3min
and then digested with digestion solution (50ml perfusion solution with
collagenase 364Uml 1, 5mg BD Difco-trypsin 250 and 20 mmol l 1 CaCl2) for 6–
7min. The atrias were removed and the ventricles were gently minced with plastic
pipettes in a 100mm dish containing 2.5ml of digestion solution. Once the
ventricles are almost completely dissolved, the digestion is stopped adding 7ml of
stopping buffer. The resulting post-digestion solutions were ﬁltered through a
100 mm ﬁlter. The cardiomyocytes were separated from ﬁbroblasts and smaller cells
by 5-min gravity sedimentation and followed by centrifuging at 100g for 30 s. The
supernatant was discarded and the pellet containing adult myocytes was
resuspended in a stopping solution (perfusion buffer contains 250mg BSA and
125 mmol l 1 CaCl2) and allowed to rest for 10min. Cells were spun down with the
same conditions described above and then underwent three steps to increase
gradient (100 mmol l 1 calcium solution: 10ml stopping buffer plus 10 ml of
100mmol l 1 CaCl2; 400mmol l 1 calcium solution: 10ml stopping buffer plus
40 ml of 100mmol l 1 CaCl2; and 900 mmol l 1 calcium solution: 10ml stopping
buffer plus 90ml of 100mmol l 1 CaCl2) to reach a ﬁnal calcium concentration of
1.025mmol l 1.
All cells were used within 2 8 h of isolation. Myocytes were plated on
laminin-coated coverslips and were bathed in HEPES-buffered (20mM, pH 7.4)
medium 199 containing 1.8mM extracellular Ca2þ .
Adenoviral constructs. To generate the adenoviral vector (Ad) encoding for the
human MR, cDNA was ﬁrst ampliﬁed from the Addgene Plasmid #23059 (ref. 53).
Next, the MR PCR product was inserted into pIRES2-EGFP (Clontech, Mountain
View, CA). This allows for co-expression of the GFP with the MR gene. The
MRiGFP was then cloned into pAd/CMV/V5-DEST (Thermo Fisher Scientiﬁc). To
generate the Ad-AT1R, the cDNA encoding for the rat AT1R with a N-terminal HA
tag was subcloned into pIRESdsRed (Clontech). The AT1RiRED was then cloned
into pAd/CMV/V5-DEST (Thermo Fisher Scientiﬁc). The Ad-vector encoding for
the bovine WT Grk2 gene (Ad-GRK2), for the WT Grk5 gene (Ad-GRK5) and one
encoding for the C-terminal region containing the last 194 amino acids of GRK2
denominated bARKct (Ad-bARKct) were previously obtained54,55. The
Ad-vector encoding for the mutated form of GRK5 lacking the nuclear localization
signal (GRK5-DNLS) was obtained previously55. The Ad-vector encoding the
mutated form of GRK2 at Ser670 (GRK2-S670A) was previously obtained29.
Ad-GFP was used as a control.
Adenoviral infection. At 24 h post-isolation, NRVMs were infected with
recombinant, replication-deﬁcient adenoviruses expressing the following
genes with their respective multiplicity of infection (MOI): GRK2 (50 MOI),
GRK2-S670A (50 MOI), GRK5-DNLS (50 MOI), GRK5 (50 MOI), bARKct (50
MOI), GFP (50 MOI) HA-tagged AT1R (50 MOI) and MR (50 MOI). Equal
particles of Ad-GFP were used to control for nonspeciﬁc adenoviral effects. Cells
were cultured for 24 h before experimentation.
GRK2, GRK5 and b-arrestin 1/2 knockdown assay. NRVMs were transfected
with speciﬁc siRNAs targeting: Grk2 (Ambion, Thermo Fisher Scientiﬁc);
Grk5 (Invitrogen-Stealth siRNA; GRK5 RSS329343, Thermo Fisher Scientiﬁc);
and b-arrestin 1/2 (Arrb1–197273; Arrb2–197276; Thermo Fisher Scientiﬁc).
Scrambled siRNAs were used as negative control (Thermo Fisher Scientiﬁc).
The transfection was performed using 5 nmol of siRNAs together with HiPerfect
Transfection Reagent (Qiagen, Germantown, Maryland, USA) according to the
manufacturer’s protocols.
Western blot analysis. Cells (NRVMs and human lymphocytes) and LV samples
(0.1mg) were lysed in a RIPA buffer with protease (cOmplete-Roche, Indianapolis,
IN, USA) and phosphatase inhibitors (PhosSTOP-Roche, Indianapolis, IN, USA)
cocktail. Protein content was quantiﬁed with the Bio-Rad BCA protein assay
(Bio-Rad Laboratories, Richmond, California, USA). Protein samples were
separated by 4–20% SDS–polyacrylamide gel electrophoresis (Thermo Fisher
Scientiﬁc), and proteins were transferred to nitrocellulose membrane (Bio-Rad
Laboratories). After blocking, with a speciﬁc blocking buffer (Odyssey, LI-COR,
Lincoln, Nebraska, USA), the membranes were incubated and probed with the ﬁrst
antibody at 4 C overnight according to manufacturer’s instructions. Then, the
proteins were stained with a corresponding Alexa Fluor 680- (1:5,000; Thermo
Fisher Scientiﬁc) or IRDye 800CW-coupled (1:5,000; Rockland Inc. Limerick, PA,
USA) secondary antibody, followed by visualization of the proteins with a LI-COR
infrared imager (Odyssey), and quantitative densitometric analysis was performed
applying Odyssey version 1.2 infrared imaging software.
Protein levels of: GRK2 (sc-562, C-15; Santa Cruz Biotechnology, 1:1,000;
05-465; EMD Millipore, Billerica, MA, USA, 1:1,000), GRK5 (05-466; EMD
Millipore, 1:2,000), GAPDH (sc-32233, 6C5; Santa Cruz Biotechnology, 1:2,000),
phospho ERK 1/2 (#9106; Cell Signaling, Danvers, MA, USA, 1:1,000), total ERK
1/2 (#9102; Cell Signaling, 1:1,000), HA (sc-7392, F-7; Santa Cruz Biotechnology,
1:1,000), b-ACTIN (A5316; Sigma-Aldrich, 1:2,000), b-ARRESTIN 1/2 (#4674; Cell
Signaling, 1:1,000), NOX4 (ab109225; Abcam, Cambridge, MA, USA, 1:1,000),
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phospho-GRK2 (pS670 44–202; Thermo Fisher Scientiﬁc, 1:1,000), voltage-
dependent anion channel (VDAC) (ab14734; Abcam, 1:5,000), HSP90 (sc-13119,
F-8; Santa Cruz Biotechnology, 1:1,000), LAMIN A/C (#2032; Cell Signaling,
1:1,000), FIBRILLARIN (sc-25397; Santa Cruz Biotechnology, 1:1,000) and
CALMODULIN (CaM, sc-137079; Santa Cruz Biotechnology, 1:1,000) were
assessed. Full scans of western blots are shown in Supplementary Fig. 9.
Cell fractionation. Membrane proteins were isolated from LV samples (0.1mg)
and NRVMs (30mm dish containing B2 106 cells) using a homogenization
buffer (0.25M sucrose, 10mM Tris-HCl (pH 7.4), 1mM EDTA and protease
inhibitors; cOmplete-Roche). The tissues were lysed by homogenization while
the cells by scraping and pipetting. Next, both the lysates were sonicated and
centrifuged for 15min at 4 C at 2,000 r.p.m. The supernatant was then centrifuged
at 54,000 r.p.m. for 30min at 4 C. The pellet was washed twice using the
homogenization buffer and then centrifuged again at the same speed. The washed
pellet was then resuspended in PBS with 0.5% TritonX-100. The ﬁnal lysate was
used for western blot analysis or stored at  80 C.
To isolate mitochondria, NRVMs (30mm dish containing B2 106 cells) and
LV specimens (0.1mg) were lysed in an ice cold mitochondrial isolation buffer
(MIB) containing: 200mmol l 1 mannitol, 70mmol l 1 sucrose, 5mmol l 1
HEPES and 1mmol l 1 EGTA, pH 7.5. The MIB was supplemented with protease
inhibitors (cOmplete-Roche). Cardiac specimens were ﬁrst homogenized using a
tissue homogenizer (PT-1200E POLYTRON), and then the lysate was subsequently
homogenized on ice by passage in a 1 cc syringe with a 27 1/2G needle (BD,
Franklin lakes, NJ, USA) twenty times. NRVMs were only homogenized by passage
in the syringe. Lysate was then centrifuged at 600g for 10min at 4 C. The
supernatant was transferred to a new 1.5ml tube and centrifuged again at 14,000g
for 15min at 4 C. The supernatant was collected in a new tube (cytosolic fraction).
While, pellet containing the mitochondria fraction was resuspended in fresh MIB
buffer and centrifuged again at 14,000g for 15min at 4 C. The washed
mitochondrial pellet was resuspended in MIB and directly used for protein
quantiﬁcation and immunoblotting. When mitochondria were taken from
NRVMs, cells were washed once with ice cold Dulbecco’s PBS, scraped into MIB
buffer and processed as described above. Nuclear fractions were obtained from
NRVMs (30mm dish containingB2 106 cells) and from LV specimens (0.1mg).
After stimulation, the cells were washed with ice cold PBS and processed using a
nuclear/cytosol fractionation kit (BioVision Inc., Milpitas, CA) according to
manufacturer’s instructions.
Confocal microscopy. NRVMs or AVMs washed three times in ice cold PBS and
ﬁxed in 3% paraformaldehyde (PFA) for 10min. Then the cells were permeabilized
with 0.2% Triton X-100 for 2min. After three washes in PBS, the cells were
incubated with 1% BSA for 30min and then incubated with an anti-HA (Santa
Cruz Biotechnology, 1:200) and anti-GRK5 (Santa Cruz Biotechnology, 1:200),
respectively, diluted in 1% BSA. Next, the cells were incubated with the respective
secondary antibodies: a mouse monoclonal to reveal the HA-tag (Alexa Fluor 647;
Thermo Fisher Scientiﬁc, 1:200) and a rabbit polyclonal to reveal GRK5 (Alexa
Fluor 546; Thermo Fisher Scientiﬁc 1:200). The ﬂuorescent data sets were visua-
lized with a Zeiss 510 confocal laser scanning microscope and analysed by LSM 510
software.
MTTassay. MTT assay, to assess the mitochondrial function56, was performed in
NRVMs as previously described57. Brieﬂy, the cells (B3 105 cells) were plated in
12-well multi-well plate and were subjected to treatments (aldosterone 12 h).
Following stimulation, aseptically MTT solution (5mgml 1 MTT in PBS;
Sigma-Aldrich) was added in an amount equal to culture volume and the cells were
incubated for 1 h. Next, MTT solvent (dimethylsulphoxide) was added to the cells
in an amount equal to the original culture volume. Further, cell plates were
subjected to gyratory shaker that enhanced dissolution of the MTT formazan
crystals, and then the reaction was read at absorbance of 590 nm with a reference
ﬁlter of 620 nm.
MitoSOX Red staining. MitoSOX Red staining (Life Sciences, Thermo Fisher
Scientiﬁc) was performed in NRVMs as previously described58. Brieﬂy, after
isolationB3 105 cells were plated in a 30mm dish and stimulated as described in
ﬁgure legends. Then, cells were incubated for 10min with 3 mM MitoSOX working
solution. After incubation, cells were washed with warm Hank’s balanced salt
solution with calcium and magnesium (HBSS/Ca/Mg) and counterstained with
DAPI Fluoromount-G (Southern Biotech, Birmingham, AL). Finally, cells were
examined with a microscope (Nikon Eclipse Ti) and images were acquired with
a digital camera (Nikon).
For each of the samples, ﬁve to six ﬁelds (NRVMs:B30–60 cells for ﬁeld) were
acquired.
TUNEL staining. TUNEL was performed on ﬁxed parafﬁn-embedded LV sections
(4mm) or on NRVMs using a commercial kit (Roche) and the assay was performed
according to manufacturer’s instructions. NRVMs (B3 105 cells) were plated in
a six-well multi-well dish and stimulated as described in ﬁgure legends. TUNEL
staining was visualized by speciﬁc red (Texas Red) or green ﬂuorescence
(ﬂuorescein) and nuclei by 40,6-diamidino-2-phenylindole (DAPI; nuclear
counterstain). All sections and cells were examined with a microscope (Nikon
Eclipse Ni) and images were acquired with a digital camera (Nikon). For each of
the samples, ﬁve to six ﬁelds (NRVMs: B100–300 cells for ﬁeld; cardiac section:
B600–1,000 cells for ﬁeld) were acquired.
Cell hypertrophy. After isolation, NRVMs (B3 105 cells) were plated in a
six-well multi-well dish and stimulated as described in ﬁgure legends. NRVMs were
then ﬁxed in 3% PFA for 10min and then washed three times in ice cold PBS and
permeabilized with 0.2% Triton X-100. Then the cells were incubated with 1% BSA
for 30min and then incubated overnight at 4 C with an anti-a-sarcomeric actinin
(a-SMA, A7811, Sigma-Aldrich; 1:200) dissolved in 1% BSA. Next, cells were
incubated with the respective secondary antibody (Texas Red conjugated;
Sigma-Aldrich; 1:200). Cells were examined with a microscope (Nikon Eclipse Ni)
and images were acquired with a digital camera (Nikon). For each of the samples,
ﬁve to six ﬁelds (NRVMs: B50 cells for ﬁeld) were acquired.
MEF2 luciferase assay. Luciferase activity was measured using a luciferase assay
system kit (Promega, Madison, WI, USA) according to manufacturer’s protocol.
NRVMs (24-well multi-well dish containingB2 105 cells) were co-infected with
the Ad-MEF2-Luc. After stimulation, cells were washed three times with ice cold
PBS and collected in passive lysis buffer (Promega). Then, luciferase activity was
measured using a plate reader (Inﬁnite M1000 PRO-TECAN).
Cell migration. Cell migration was assessed by wound-healing scratch assay as
previously described59. After isolation, cardiac ﬁbroblasts (B3 105) were plated
in 12-well tissue culture plates. Twenty-four hours after plating, scratches were
made using 100 ml pipette tips and the wells were washed twice with PBS. Then the
cells were stimulated with conditioned media from NRVMs stimulated with
aldosterone (1 mM) for 24 h. Following 3 and 12 h of stimulation, the cells were
ﬁxed in 3.7% paraformaldehyde and stained with 0.1% crystal violet staining
solution. Photographs were taken on Nikon TE inverted microscope connected to a
Nikon camera. Quantiﬁcation of cell migration was performed by measuring the
distance between 10 random points within the wound edge. Gap distance of the
wound was measured using ImageJ software, and the data were normalized to the
average of the wound of control cells ﬁxed at the time of scratches.
Animal models. All animal procedures were performed in accordance with the
guidelines of the Institutional Animal Care and Use Committee of Temple
University School of Medicine. For in vivo experiments, we used WT C57BL/6
mice and conditional mice bearing ﬂoxed Grk2 (Grk2-ﬂ/ﬂ), which have
previously been described29,60. In addition aMHC-Cre mice15 were bred on to the
Grk2-ﬂ/ﬂ background to generate cardiac Grk2 KO mice or to Grk5-ﬂ/ﬂ
background to generate cardiac Grk5 KO mice31, initiated by the activation of the
aMHC-promoter and were included in the study61. All animals (female and males,
9–10 weeks) were bred and maintained on a C57Bl/6 background.
Aldosterone infusion in mice. As previously described44, aldosterone (2mg per
mouse per day) dissolved in PBS and 5% ethanol was continuously infused
subcutaneously into mice via an osmotic minipump (ALZET, DURECT Co.,
Cupertino, USA) for 4 weeks. A control group was infused only with PBS and 5%
ethanol (vehicle). Mice were anesthetized with isoﬂurane (2.5% (vol/vol)) and
pumps were implanted subcutaneously through a sub-scapular incision, which was
then closed using 4.0 silk suture (Ethicon). After 4 weeks of infusion, transthoracic
echocardiographic studies were performed, and then blood samples were collected
by puncturing the heart, and heart samples were excised for pathological
examination and immunohistochemistry.
Echocardiography. Four weeks after aldosterone treatment, transthoracic
echocardiography was used to assess cardiac structure and function and performed
using a VisualSonics VeVo 2100 system (VisualSonics, Toronto, Ontario, Canada).
Mice were anesthetized in a speciﬁc isoﬂurane sedation box (induction 3.0% and
maintenance 1–3%). Mice were next shaved to remove hair from the ventral thorax
(from the neckline to mid-chest level). Then, mice were placed in a supine position
on a heated table with embedded ECG leads. During echocardiography anaesthesia
was maintained throughout the procedure with 1–3% isoﬂurane. LV diameters and
subsequently fractional shortening were evaluated with a 18–38MHz probe. We
ﬁrst performed two-dimensional imaging to obtain a view along the parasternal
short axis at the level of the greatest LV dimension, that include the left ventricle
and a slight portion of the right ventricle. Next, we will use M-mode echo-
cardiography, which provides a one-dimensional view, to obtain ﬁne measure-
ments of cardiac dimensions (LV end-diastolic and end-systolic diameter and LV
anterior and PW thickness) and contractility (ejection fraction and fractional
shortening). End diastole was determined at the maximal LV diastolic dimension
and end systole was taken at the peak of PW motion.
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Histology. Cardiac specimens were ﬁxed in 4% formaldehyde embedded in
parafﬁn. After de-parafﬁnization and re-hydration, 5-mm-thick sections were
prepared, mounted on glass slides and stained with 1% Sirius red in picric acid
(Sigma-Aldrich) to detect interstitial ﬁbrosis. The percentage of ﬁbrosis was
quantiﬁed using a software (ImageJ). All sections were examined with a microscope
(Nikon Eclipse Ni) and images were acquired with a digital camera (Nikon).
Real-time PCR. Total RNA was isolated from NRVMs and from LV specimens
with TRIzol (Thermo Fisher Scientiﬁc) according to the company’s instructions.
After RNA isolation, cDNA was synthesized by reverse transcription of the RNA
(iScript cDNA synthesis kit, Bio-Rad Laboratories). Real-time PCR was performed
in duplicate on a CFX96 real-time PCR detection system (Bio-Rad Laboratories)
using the SYBR Green mix (Bio-Rad Laboratories) and speciﬁc primers for mouse
Ctgf as follows: forward 50-GGAAGACACATTTGGCCCAG-30 ; reverse 50-TAG
GTGTCCGGATGCACTTT-30 .
The expression levels of CTGF were normalized to the rRNA 18S. Speciﬁcity of
PCR products was conﬁrmed by melting curve and gel electrophoresis.
Enzyme-linked immunosorbent assay. Aldosterone serum levels were measured
in mice using a commercial kit (KA1883; Abnova, Walnut, CA, USA) and the assay
was performed according to manufacturer’s instructions. The assay was performed
on blood serum isolated from aldosterone-treated (4 weeks) mice. Blood (300 ml)
was collected by puncturing the heart. Then, blood samples were centrifuged at
1,500 r.p.m. for 15min at room temperature and the serum was transferred to a
1.5ml tube. Blood serum isolated from vehicle-treated mice was used as control.
Lymphocytes GRK2 protein levels in human HF patients. We studied 127
patients with an established diagnosis of HF enroled at Federico II University
(Naples, Italy) and Salvatore Maugeri Foundation, Scientiﬁc Institute of
Telese Terme (Telese Terme, BN, Italy). All patients signed consent form. The
patients’ inclusion criteria were as follows: diagnosis of HF due to ischaemic
or non-ischaemic aetiology, LV ejection fraction (LVEF) r45%, stable clinical
conditions for at least 1 month before inclusion and guideline-based optimal
pharmacotherapy. All subjects underwent a complete clinical examination
(including New York Heart Association (NYHA) functional class assessment and
echocardiography) and blood draw (3ml) for lymphocyte isolation. The blood,
collected in a tube containing EDTA (Vacutainer-BD, Franklin Lakes, NJ, USA),
was diluted with an equal volume of PBS. The diluted blood was layered over 3ml
of Lympholyte-H Cell Separation Media (Cedarlane, Burlington, NC, USA) and
centrifuged for 20min at 800g. The lymphocyte layer was transferred to a new tube
using a Pasteur pipette. The transferred cells were diluted with PBS and centrifuged
at 800g for 10min to pellet the lymphocytes. After three washes with PBS, the cells
were centrifuged as above and the supernatant was removed. The resulting lym-
phocyte pellet was stored at  80 C and lysed, and was analysed by immunoblot
for GRK2 levels, as described above. Demographic data including age, sex, HF
medications and cardiovascular risk factors and presence of comorbidities were
also collected.
Statistics. Data are expressed as mean±s.e. Statistical signiﬁcance was
determined by a Student’s t-test or Mann-Whitney exact test (when sample size
was o10). For multiple comparisons, one-way analysis of variance (ANOVA)
followed by Bonferroni post hoc correction was performed. Categorical variables
were expressed as proportion and compared by use of w2 test. All data were
analysed using GraphPad Prism software version 6. Statistical signiﬁcance was
accepted at Po0.05.
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